MedPage Today -- Patients with non-small cell lung cancer (NSCLC) had significantly higher levels of circulating genetically abnormal cells compared with cancer-free patients -- suggesting that a DNA-based test might be valuable for early diagnosis, according to data from an initial clinical study.
